Open Access Open Access  Restricted Access Subscription or Fee Access

Oral Delivery of Human Therapeutic Proteins: Current Status and Future Challenges

Abhay Kumar, Prafulla Kumar

Abstract


Oral delivery of protein drugs is one of the highly attractive approach in today’s world, which leads to many attempts for development of such formulations. In spite of numerous attempts, however, no clinically impactful oral formulations have been developed, due to extremely low bioavailability of protein drugs. This is due to barriers related to poor absorption, poor permeation, and degradation in the gastrointestinal tract. So, the effective oral protein delivery needs to overcome these barriers. However numerous strategies have been made and explored for improving the bioavailability of orally administered proteins. Which consists of modification of protein drugs chemically, use of enzyme inhibitors, and use of unique formulation components, such as absorption enhancers and mucoadhesive polymers. This article examines the current technologies under development for oral protein delivery.

Full Text:

PDF

References


J. Shaji, V. Patole. Protein and Peptide Drug Delivery: Oral Approaches.

Y. Li, Z. Duan, Y. Tian, Z. Liu, Q. Wang. Novel perspective and approach to intestinal octreotide absorption: sinomenine-mediated reversible tight junction opening and its molecular mechanism.

A. Fasano, S. Uzzau. Modulation of Intestinal Tight Junctions by Zonula Occludens Toxin Permits Enteral Administration of Insulin and Other Macromolecules in an Animal Model.

B. J. Aungst. Absorption Enhancers: Applications and Advances.

T. Uchiyama, T. Sugiyama, Y.S. Quan, A. Kotani, N. Okada, T. Fujita, S. Muranishi, A. Yamamoto. Enhanced permeability of insulin across the rat intestinal membrane by various absorption enhancers: their intestinal mucosal toxicity and absorption-enhancing mechanism of n-lauryl-beta-D-maltopyranoside.

A. Yamamoto, Hiroyuki, Tatsumi, M. Maruyama, T. Uchiyama, N. Okada, T. Fujita. Modulation of intestinal permeability by nitric oxide donors: implications in intestinal delivery of poorly absorbable drugs.

A. Yamamoto, T. Uchiyama, R. Nishikawa, T. Fujita, S. Muranishi. Effectiveness and toxicity screening of various absorption enhancers in the rat small intestine: effects of absorption enhancers on the intestinal absorption of phenol red and the release of protein and phospholipids from the intestinal membrane.

M. Di Pierro, R. Lu, S. Uzzau, W. Wang, K. Margaretten, C. Pazzani, F. Maimone, A. Fasano, Z. Occludens. Toxin Structure-Function Analysis.

W. Wang, S. Uzzau, S.E. Goldblum, A. Fasano, H. Zonulin. A potential modulator of intestinal tight junctions.

M. Thanou, J.C. Verhoef, H.E. Junginger. Chitosan and its derivatives as intestinal absorption enhancers.

R.E. Hulse, L.A. Ralat, W.-J. Tang. Structure, function, and regulation of insulin-degrading enzyme.

E. Toorisaka, M. Hashida, N. Kamiya, H. Ono, Y. Kokazu, M. Goto. An enteric-coated dry emulsion formulation for oral insulin delivery.

P.R. Kulkarni, J.D. Yadav, K.A. Vaidya. Liposomes: a novel drug delivery system.

H.-I. Chang, M.-Y. Cheng, M.-K. Yeh. Clinically-proven liposome-based drug delivery: formulation, characterization and therapeutic efficacy.

T.R. Kyriakides, C.Y. Cheung, N. Murthy, P. Bornstein, P.S. Stayton, A.S. Hoffman. pH-sensitive polymers that enhance intracellular drug delivery in vivo.

S. Sakuma, M. Hayashi, M. Akashi. Design of nanoparticles composed of graft copolymers for oral peptide delivery.

P. Martin. Beyond the next generation of therapeutic proteins.

N.A. Peppas, K.M. Wood, J.O. Blanchette. Hydrogels for oral delivery of therapeutic proteins.

M.R. Rekha, C.P. Sharma. Oral delivery of therapeutic protein/peptide for diabetes – Future perspectives.

http://www.google.co.in/url?sa=t&rct=j&q=&esrc=s&source=web&cd=2&ved=0CDUQ FjAB&url=http%3A%2F%2Fwww.sigmaaldrich.com%2Fetc%2Fmedialib%2Fdocs%2FSig ma%2FProduct_Information_Sheet%2F1%2Ft9777pis.pdf&ei=OyWYUv3qJo7NrQe- 4YDwDQ&usg=AFQjCNGuGWyfCHUMi15p5y4DEMevl43o1A&sig2=3o9D5swR9H6P4 apmIrRAkg&bvm=bv.57155469,d.bmk.

Liener IE, Goodale RL, Deshmukh A, Satterberg TL, Ward G, DiPietro CM, Bankey PE, Borner JW,Effect of a trypsin inhibitor from soybeans (Bowman-Birk) on the secretory activity of the human pancreas.

Andreas Bernkop-Schnürch, Mucoadhesive systems in oral drug delivery.

http://www.pharmainfo.net/reviews/comparative-review-recently-developed-particulate- drug-carrier-systems.

K. Srikant, V. Rama Mohan Gupta, Sunder Raj Manvi, N. Devanna, Particulate carrier system.

N. Mishra, A.K. Goyal, K. Khatri, B. Vaidya, R. Paliwal, S. Rai, A. Mehta, S. Tiwari, S. Vyas, S.P. Vyas. Biodegradable Polymer Based Particulate Carrier(s) for the Delivery of Proteins and Peptides.

J.D. Vaghjiani, T.S. Lee, G.J. Lye, M.K. Turner. Production and characterisation of cross-linked enzyme crystals (CLECs (R)) for application as process scale biocatalysts.

https://www.google.co.in/search?q=BioSante:+Bio+Oral+system+%28calcium+phosphate+na noparticles%29&safe=active&source=lnms&tbm=isch&sa=X&ei=ZGOYUvL1BoS_rgetuYD4D g&ved=0CAcQ_AUoAQ&biw=1366&bih=654#facrc=_&imgdii=_&imgrc=G- FNc5iTw8EMwM%3A%3BOfUyu-CgWfWzGM%3Bhttp%253A%252F%252Forigin-ars.els- cdn.com%252Fcontent%252Fimage%252F1-s2.0-S0378517304001395- gr1.jpg%3Bhttp%253A%252F%252Fwww.sciencedirect.com%252Fscience%252Farticle%252F pii%252FS0378517304001395%3B416%3B203.

http://www.pharmaloco.com/news_detail/BioSante+Pharmaceuticals+Announces+Positive+O ral+Insulin+Stu/29749/index.html.

http://www.news-medical.net/news/2004/06/02/2074.aspx.

http://www.prnewswire.com/news-releases/nobex-issued-two-significant-us-patents-for- small-peg-based-polymers-53828312.html.

http://www.biocon.com/biocon_research_discovery.asp.

http://www.biocon.com/biocon_press_release_details.asp?subLink=news&Fileid=459.




DOI: https://doi.org/10.37628/ijmb.v3i2.223

Refbacks

  • There are currently no refbacks.